share_log

Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $53 Price Target

Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $53 Price Target

Needham重申買入Rocket Pharmicals,維持53美元的目標股價
Moomoo 24/7 ·  04/10 06:08

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

Needham分析師吉爾·布魯姆重申了火箭製藥公司(納斯達克股票代碼:RCKT)的買入並維持53美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論